Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Thromboprophylaxis in Lower Extremity Fracture
NCT00881088Phase 3Unknown
- Sponsor
- Rode Kruis Ziekenhuis
- Start
- Apr 2009
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of nadroparin and fondaparinux in venous thromboembolism (VTE) (3 arms), sponsored by Rode Kruis Ziekenhuis. Primary endpoint: Deep Vein Thrombosis at 6 weeks. Status: unknown.
02
Drugs
nadroparinfondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00881088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881088.